- Home
- ANAB vs TRIP Comparison
ANAB vs TRIP Comparison
Compare ANAB & TRIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ANAB | TRIP |
|---|---|---|
| Founded | 2005 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Programming Data Processing |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.6B |
| IPO Year | 2017 | 2011 |
Fundamental Metrics
Financial Performance| Metric | ANAB | TRIP |
|---|---|---|
| Price | $47.66 | $13.01 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 12 | 10 |
| Target Price | ★ $60.18 | $15.98 |
| AVG Volume (30 Days) | 499.2K | ★ 2.4M |
| Earning Date | 02-26-2026 | 02-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 124.53 |
| EPS | N/A | ★ 0.59 |
| Revenue | $169,467,000.00 | ★ $1,891,000,000.00 |
| Revenue This Year | $135.51 | $5.18 |
| Revenue Next Year | N/A | $4.97 |
| P/E Ratio | ★ N/A | $22.30 |
| Revenue Growth | ★ 196.42 | 4.25 |
| 52 Week Low | $12.21 | $10.43 |
| 52 Week High | $52.47 | $20.16 |
Technical Indicators
Market Signals| Indicator | ANAB | TRIP |
|---|---|---|
| Relative Strength Index (RSI) | 53.20 | 34.74 |
| Support Level | $46.06 | $12.98 |
| Resistance Level | $50.00 | $14.05 |
| Average True Range (ATR) | 3.02 | 0.52 |
| MACD | -0.05 | -0.10 |
| Stochastic Oscillator | 64.38 | 1.42 |
Price Performance
Historical ComparisonAbout ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
About TRIP TripAdvisor Inc.
Tripadvisor is the world's leading travel metasearch company. Its platform offers 1 billion reviews and information on several million accommodations, restaurants, experiences, airlines, and cruises. In 2024, 52% of revenue came from the company's core Brand Tripadvisor segment, which includes hotel revenue generated through advertising on its metasearch platform. Viator, its experiences brand, was 46% of revenue in 2024, and TheFork, its dining brand, represented 10% of sales (about 8% of revenue were intersegment, which are eliminated from consolidated revenue).